Cergutuzumab (RG7813) is a tumor-targeted immunocytokine comprising a humanized anti-CEA monoclonal antibody fused to an engineered interleukin-2 variant (IL-2v). By specifically binding to Carcinoembryonic Antigen (CEA) on tumor cells, Cergutuzumab delivers IL-2v directly to the tumor microenvironment. This selectively activates cytotoxic CD8+ T cells and NK cells while minimizing the systemic toxicity typically associated with wild-type IL-2 therapy.